Nonacog alfa

Drug Profile

Nonacog alfa

Alternative Names: BeneFIX; Coagulation Factor IX (Recombinant) - Pfizer; Factor IX - Wyeth; Recombinant Factor IX - Wyeth

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator University of Oxford; Washington Research Foundation
  • Developer Pfizer
  • Class Antihaemorrhagics; Blood coagulation factors
  • Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 05 Aug 2016 Takeda and Pfizer terminates its commercialisation agreement for nonacog alfa in Japan
  • 08 Mar 2016 Updated efficacy data from a phase III trial in Haemophilia B released by Pfizer
  • 03 Mar 2015 No recent reports on development identified - Phase-III for Haemophilia B (Prevention) in USA, Hungary, Italy, Romania, Russia, Serbia and Spain (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top